Henry Liberman, MD
Interventional Cardiology · Lawrenceville, GANPI 1356358741
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,080 of the $5,821 with a category attached, or 70.1%. 26 manufacturers reported payments, led by Medtronic at 36.4% of the total. Reporting peaked in 2020 at $2,201 and has fallen 66.0% since, to $748 in 2025. That places this record below the midpoint for interventional cardiology clinicians in GA, where the typical reported total is $7,640.
Across 122 payments — averaging $47.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Novartis$524
- Abbott$476
- AstraZeneca$344
- Biotronik Inc.$343
- Amgen$288
- plus $2K from 20 others
Across 14 payments — averaging $7406.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$98K
- Abbott$6K
What the payments were for
- Speaking & faculty fees$1,68829%
- Travel & lodging$331%
- Food & beverage$4,08070%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 10 | $2,118 |
| Novartis | 25 | $524 |
| Abbott | 5 | $476 |
| AstraZeneca | 18 | $344 |
| Biotronik Inc. | 4 | $343 |
| Amgen | 12 | $288 |
| Novo Nordisk | 8 | $246 |
| Boston Scientific | 6 | $207 |
| Inari Medical, Inc. | 1 | $183 |
| E.r. Squibb & Sons, L.L.C. | 7 | $178 |
| Penumbra, Inc. | 1 | $149 |
| Abiomed | 1 | $135 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $90 |
| Shockwave Medical, Inc | 1 | $89 |
| Philips North America LLC | 1 | $75 |
| W. L. Gore & Associates, Inc. | 1 | $59 |
| Johnson & Johnson | 3 | $55 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $50 |
| Esperion Therapeutics, Inc. | 3 | $47 |
| Boehringer Ingelheim | 2 | $43 |
| Inspire Medical Systems, Inc. | 1 | $27 |
| Pfizer | 1 | $26 |
| Lantheus Medical Imaging, Inc. | 1 | $21 |
| Merck | 1 | $19 |
| Heartflow, Inc. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Resolute$1,831
- FLOWTRIEVER CATHETER, S$367
- AMPLATZER AMULET$167
- Rivacor 7 DR-T$150
- Orsiro Mission$150
- BioMonitor$150
- PK Papyrus$150
- Acticor 7 VR-T DX$150
- Indigo System$149
- DRAGONFLY OPSTAR$145
- Euphora$138
- Impella$135
- PORTICO$128
- Repatha$106
- Ozempic$100
How this compares
$5,821 in reported general payments places this provider in the 40th percentile of 218 interventional cardiology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 56 | $64,601 |
| FarxigaDapagliflozin Propanediol | 19 | $17,079 |
| Repatha SureclickEvolocumab | 11 | $14,822 |
| Rosuvastatin Calcium | 96 | $1,343 |
| Metoprolol Succinate | 82 | $1,146 |
| Nifedipine ErNifedipine | 15 | $1,020 |
| Carvedilol | 54 | $703 |
| Isosorbide Dinitrate | 13 | $639 |
| Atorvastatin Calcium | 84 | $564 |
| Ezetimibe | 26 | $553 |
| Losartan Potassium | 27 | $416 |
| Amlodipine Besylate | 69 | $339 |
| Lisinopril | 50 | $293 |
| Hydralazine Hcl | 13 | $288 |
| Furosemide | 35 | $223 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $26 | $64,60156 claims |
| AstraZenecaFarxiga | $344 | $17,07919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 218 interventional cardiology providers in Georgia.
Other interventional cardiology in Lawrenceville
- Philip RommLawrenceville$52K
- William NicholsonAtlanta$1000K
- David KandzariAtlanta$982K
- Pradeep YadavAtlanta$656K
- Salvatore ManninoMarietta$275K
- Megan CoylewrightCalhoun$271K
- Paul GuichardMarietta$260K
- Adam GreenbaumAtlanta$238K
- Wissam JaberAtlanta$222K
- Mudassar AhmedGainesville$193K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.